Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of…
![Resta in [u]contatto[/u]](/static/paper-plane.svg)
Recording of virtual meeting – Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention…
COURAGE-ALS trial discontinued due to disappointing results
The company Cytokinetics has announced early termination of the COURAGE-ALS study. An…
TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear…
Lo Studio ATLAS: uno studio clinico per le persone che vogliono contribuire alla ricerca sulla SOD1 nella SLA
Lo studio clinico valuta l’efficacia e la sicurezza di un farmaco sperimentale…
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials,…
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS…
USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give…
Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
The UK government has recently announced that £50 million will be invested…
A road map for digital health care technology in MND
The COVID-19 pandemic has had an important impact on the development and…